April 2026

EBO Editor in Chief Sucharu "Chris" Prakash, MD, addresses the role of nutrition in cancer prevention and treatment.

Prior authorization and PBM utilization management delay oncology and hematology novel therapies, shifting reimbursement risk to patients in Medicare Advantage.

KFF Health Tracking Poll finds prior authorization tops patient hassles; Drew Altman, PhD, warns complexity delays care, hitting chronic patients hardest.

Value-based care in oncology: why CMS’ models have fallen short and how new partners can sustain navigation, symptom monitoring, and savings.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Discussions at this February IVBM evening covered advances in biomarker testing in lung cancer to the real-life challenges of maintaining diversity in clinical trials.

Oncology leaders appearing in Atlanta, Georgia, including several from Winship Cancer Institute from Emory University School of Medicine, show how NGS biomarkers and MRD reshape NSCLC and hematology care, tackling payer hurdles and health equity gaps.

Panelists at a Boston Regional Institute for Value-Based Medicine event examined trial diversity, integrated dispensing, and evolving oncology pathways.

Thyme Care bets on ePRO-driven toxicity monitoring to cut Medicare oncology adverse events, infections and ED visits—making value-based care finally work.

With radiopharmaceutical therapy use up 20 times in Medicare, experts analyze clinical pathways for delivering it in academic and community settings.

New bipartisan legislation would ban parent companies from owning insurers or PBMs and providers or management services organizations simultaneously.

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.

The ACCESS Model signals a shift toward outcome-aligned payments and a necessary reframing of what “value” actually means.